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ABSTRACT
Hyperhomocysteinemia (Hhcy) is a biochemical abnormality characterized by abnormally large levels of homocysteine (Hcy) in blood. Hcy is a highly 
reactive sulfur-containing amino acid derived from methionine, an essential amino acid. Excess Hcy produced in the body is excreted out of the tightly 
regulated cell environment into the blood. It is the role of the liver and kidney to remove excess Hcy from the blood. Hhcy increases the generation 
of reactive oxygen species by activating nicotinamide adenine dinucleotide phosphate oxidase. It downregulates the endothelial nitric oxide (NO) 
synthase and thus reduces the bioavailability of NO. Moreover, it increases the production of proinflammatory cytokines like tumor necrosis factor-α 
by activating nuclear factor-kappa B. Hhcy is caused by the excess deficiencies of the vitamins such as pyridoxine (B6), folic acid (B9), or B12 and is 
considered as an independent risk factor for various cardiovascular diseases such as endothelial dysfunction, vascular inflammation, atherosclerosis, 
hypertension, cardiac hypertrophy, and heart failure. Many evidences are available which suggest that ignoring Hcy levels in patients with the vascular 
disease would be unwise. Thus, there is an urgent need for health care providers to develop effective preventions and interventions program (folic 
acid, Vitamin B6, and Vitamin B12 supplementation as well as lifestyle change) to reduce this disorder.
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INTRODUCTION
Hyperhomocysteinemia (Hhcy) is a disorder characterized by an 
abnormal increased level of homocysteine (Hcy) in the blood, above 
15 μmol/L [1]. Jukes reported that Hcy is a sulfur-containing amino 
acid, isolated from a urinary bladder stone in 1933 by Vincent du 
Vigneaud [2]. It has been under a lot of speculation since its discovery. 
Its chemical property showed a similarity to cysteine; hence, the name 
is Hcy. Hcy is an amino acid produced via demethylation of dietary 
methionine, which is abundant in animal protein [3,4]. It is the role 
of the liver and kidney to remove excess Hcy from the blood. People 
with Hhcy get blood clots in their veins and arteries (e.g., deep vein 
thrombosis and pulmonary embolism). Hcy is a key determinant of the 
methylation cycle. It is metabolized either by remethylation pathway to 
methionine or the transsulfuration pathway to cysteine. Condensation 
of methionine with adenosine triphosphate (ATP), leads to the 
formation of s-adenosylmethionine (SAM), a principle methyl donor 
for all methylation reactions in cells [5,6]. The demethylation reaction 
leads to the formation of s-adenosylhomocysteine (SAH) which further 
leads to the formation of Hcy and adenosine. The former pathway of 
Hcy metabolism is dependent on the proper functioning of methylene 
tetrahydrofolate reductase (MTHFR) enzyme, methionine synthetase, 
Vitamin B12, and folic acid. The later pathway is dependent on the 
enzymes cystathionine beta-synthetase and MTHFR [7].
The prevalence of Hhcy varies widely with geography, sex, ethnicity, and 
age, for example, Amouzou and coworkers reported that coastal West 
Africa people had a higher prevalence of Hhcy than the people located 
in an interior part of countries. The incidence of Hhcy in the American 
population is just 5-7%, in Chinese is 27.5%, and in Indians is 52-84%. 
Indians were found to have higher Hcy levels than Europeans. It is 
estimated that mild Hhcy occurs in 5-7% of the general population and 
40% of patients with vascular disease. The incidence of homocystinuria 
in the United States is approximately 1 per 100,000. In 1990-98, stroke 
mortality in the US was falling at 0.3% a year but after folate substitution 
in 1998, the mortality dropped to 2.9% per year, a 10 times change. 
The frequency of polymorphism (common mutation in MTHFR gene) is 
very low in some populations (<1% in African descent) and very high 
in others (11-15% in Anglo-Americans, >20% in Italian, Hispanic, and 
Columbians and 25-57% in Mexican population). Bangladeshi men 
have a high prevalence of Hhcy, which is associated with smoking and 
betel nut use [8,9].
CAUSES OF HHCY
Dietary factor
Hcy elevation occurs because of poor diet (absence of essential food 
components). If a person takes high protein rich diet daily, i.e., meat, 
egg, chicken, milk, etc., he should also incorporate certain vital amines 
in his diet. The absence of these vital amines causes Hhcy [10].
Life style factors
Smoking is associated with vascular disease and other complications 
related to Hhcy. The number of cigarettes smoked a day is the strongest 
determinants of Hcy levels. Nicotine directly affects the methylation and 
catabolises folate cycle. Physical activity plays an important role in life 
since it is the cheapest way of strengthening our health and reduces the 
risk of cardiovascular diseases (CVD). Physical inactivity decreases the 
concentrations of total plasma Hcy, and thus increases the probability 
of developing CVD in healthy and already sick people. Hhcy increases 
with age, changes in gastrointestinal function, B Vitamins deficiency, 
enzyme defects, and a higher occurrence of the C677T mutation occur 
in elderly [11].
Vitamin deficiency
Vitamin B6, B12, and folic acid are needed for the enzymes involved in 
Hcy metabolism; high protein intake seems to lower Hcy levels. Strict 
vegetarians are often at risk for Hhcy due to low plasma B12 levels. 
Coffee consumption (4 cups/day) is linked to moderate elevations 
in Hcy, although this effect can be countered by supplementing with 
200 mg/day of folic acid. Diagnosis is made by measuring the level of 
total Hcy in the blood. Patients having the diseases such as dyslipidemia, 
diabetes, renal insufficiency, Alzheimer disease, and hypertension 
should be tested for Hhcy. Hcy is tested by chromatographic 
method, immunoassay method, enzyme cycling method, capillary 
electrophoresis, and chemosensors. Blood vessels abnormalities, 
atherosclerosis, mental retardation in children, thrombosis, and bone 
loss are common symptoms of Hhcy [12,13].
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Alcohol induced
Chronic intake of alcohol consumption interferes in the metabolism 
of folic acid and cyanocobalamin. It is associated with gastrointestinal 
disturbances, which result in decrease absorption of vitamins and folic 
acid, thus contributing to elevated Hcy levels. It also inhibits methionine 
synthase to decrease hepatic uptake and increase excretion via urine.
Drug induced
Certain drugs such as cholestyramine and metformin prevent vitamin 
absorption from the gut. Methotrexate, nicotinic acid, and fibric acid 
derivatives interfere with folate and Hcy metabolism. Oxcarbazepine 
and topiramate might cause Hhcy because of their capacity to activate 
hepatic enzymes.
Renal dysfunction
Renal failure patients have extremely high Hcy levels due to less 
efficient renal clearance of Hcy. Patients with kidney disease have high 
rates of cardiovascular morbidity and death is observed. It exhibit 
disproportionately elevated plasma with Hcy levels. Hcy levels increase 
as renal function declines. The underlying cause of Hhcy in renal 
disease is not yet understood, although reduced plasma Hcy clearance 
is the most proximate cause [14,15].
Genetic factors
Hhcy is caused either by genetic defects in the enzymes which 
are involved in Hcy metabolism or by nutritional deficiencies in 
vitamin cofactor. Genetic defects in genes encoding for enzymes 
such as methyl tetrahydrofolate (THF), methionine synthase, and 
cystathionine-β-synthase causes a deficiency. Methyl THF enzyme 
is responsible for the conversion of 5,10 methylenetetrahydrofolate 
to 5-methyltetrahydrofolate. German and Italian population show 
different incidences of 24.5% and 43.8% of genetic defects in genes 
encoding for these enzymes. Certain rare defects in this gene cause 
homocystinuria, brain damage, and childhood CVD [16].
MOBILIZATION OF HCY PATHWAY
Hcy is a sulfur-containing amino acid which is generated from the 
metabolism of methionine, the metabolism of which involves four 
steps. The first step is transmethylation pathway which involves the 
conversion of methionine to Hcy [17]. This pathway involves the 
formation of SAM, which transfers a methyl group to a number of 
several methyl acceptor molecules (proteins, DNA, neurotransmitters) 
and forms adenosylhomocysteine, which is subsequently converted 
to Hcy. The second step is the transsulfuration pathway that involves 
the irreversible conversion of Hcy to cysteine in the presence of 
cystathione-β-synthase and Vitamin B6 as an essential cofactor. The 
third step is the re-methylation pathway in which regeneration of 
methionine occurs from Hcy by methionine synthase along with 
MTHF – 5 Methyltetrahydrofolate and Vitamin B12 as essential 
cofactors. The last step is the regeneration of methylenetetrahydrofolate 
(MTHF) from THF, which is catabolized by enzyme 5, 10-methelene-
tetrahydrofolate reductase [18,19] (Fig. 1).
TREATMENT
The internationally accepted treatment for Hhcy involves the use of 
vitamins, i.e. folic acid, Vitamin B12, and pyridoxine. Folic acid and 
vitamin predominantly act under fasting condition and pyridoxine 
acts after meals. Pyridoxine reduces Hcy levels by 22%. Folic acid 
alone reduces Hcy level by 22% and Vitamin B12 by 11%. When both 
administered together, it causes a reduction of 38.5%. Pyridoxine 
(10.250 mg/d) lowers an abnormal Hcy level in most patients [20]. 
Daily dose of 100 mg or less can precipitate peripheral neuropathy [21]. 
Treatment also includes anticoagulant medications such as aspirin, 
clopidogrel, heparin, warfarin, to prevent blood clots. Amount of 
methionine diet is restricted. Atorvastatin (10 mg) along with three 
Hcy lowering vitamins (methylcobalamin 500 mcg, folic acid 5 mg, 
and pyridoxine 10 mg) progressed in diabetic patients. Daily intake of 
(400-800 μg/day folic acid, 500 μg/day B12, and 25-100 mg/day B6) 
improves Hhcy. It is estimated that in typical Western populations, 
supplementation with a combination of 0.5-5 mg folic acid, and 0.5 mg 
Vitamin B12 daily would reduce blood Hcy concentrations by about 
one-quarter to one-third [22,23].
RISK FACTORS
Cardiac impairment
The relationship between Hhcy and atherosclerosis was suggested 
by McCully in 1969. It is now well accepted that Hhcy is a strong, 
independent risk factor for stroke, myocardial infarction, and other 
vascular events [24]. Hcy is an unstable amino acid, which undergoes 
auto oxidation to produce free oxygen radicals which further increases 
oxidative stress. It contributes to atherosclerosis in two ways. The former 
one includes free oxygen radicals converts low-density lipoproteins 
of sub endothelial tissues to oxidized low-density lipoproteins (LDL). 
Oxidized LDL further acts as a key mediator of the inflammatory 
process in atherosclerosis. Oxidized LDL causes the release of vascular 
cell adhesion molecule and monocyte chemo attractant protein [25-27]. 
The monocytes then get converted to macrophages, which take up 
oxidized LDL to get converted to foam cells. The foam cells get deposited 
below the endothelium to form fatty streak. The latter part includes the 
suppression of nitric oxide activation by free radicals, which results in 
endothelial dysfunction and contributed to atherosclerosis [28].
Stroke
Stroke is a major cause of morbidity and mortality worldwide. 
Along with hypertension, dyslipidemia, smoking, diabetes mellitus 
(DM), obesity, and family history, Hhcy is one such risk factor for 
stroke. There is epidemiological evidence suggesting a relationship 
between Hhcy and neurodegenerative conditions including Alzheimer, 
Parkinson disease, and stroke [29]. Energy metabolism and oxidative 
stress are related to the pathogenesis of this disease. Energy demands 
of central nervous system are fulfilled with continuous supplies of 
oxygen and glucose from the blood flow. Increased Hcy level reduces 
ATP availability for neurons and causes severe neuronal injury. The 
disrupted metabolism of Hcy is associated mainly with tissue hypoxia 
and vascular disease [30]. Liver, kidney, and lens cells have the ability 
to convert Hcy to methionine through a B12-independent reaction 
catalyzed by betaine homocysteine methyltransferase (BHMT). This 
reaction requires dietary betaine or endogenous choline. Central 
nervous system lacks BHMT, being thus dependent on folate and 
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Fig. 1: Diagrammatic representation of metabolic pathway 
of homocysteine (Hcy) (1) Transmethylation: conversion of 
methionine to Hcy. (2) Transsulfuration: irreversible conversion 
of Hcy to cysteine via cystathione-β-synthase. (3) Re-methylation: 
regeneration of methionine from Hcy mediated by methionine 
synthase, 5,10-methylenetetrahydrofolate (MTHF) and 
Vitamin B12 as essential cofactors. (4) Regeneration of 
5 Methyltetrahydrofolate (MTHF) from tetrahydrofolate 
catabolized by enzyme 5,10-methelene-tetrahydrofolate 
reductase
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Vitamin B12 for the conversion of Hcy to methionine. Hcy is an 
important endothelial aggression factor which promotes endothelial 
dysfunction and leads to atherosclerotic plaque formation. It inhibits 
the growth of endothelial cells, induces an imbalance between oxygen 
and NO with deleterious effects on the vascular physiology. It induces 
the expression of different adhesion molecules and promotes the 
formation of modified LDL particles, which are important players in 
atherosclerotic plaque formation [31].
Cancer risk
For the past several years, a link has been established between certain 
cancers and elevated plasma Hcy. Increased plasma Hcy concentration 
is a risk factor for cancer and even as a novel tumor marker [32]. Folate 
depletion promotes the development of cancer, particularly colorectal 
cancer 6-10, whereas high doses of folic acid enhance the growth of 
cancer cells. Folate, Vitamin B12, and Vitamin B6 have a number of 
biologic roles that make them potentially important in cancer. Hhcy 
is the most common condition highly associated with both venous 
and arterial thrombosis in many cancer patients while the associated 
pathophysiology has not been established yet. Defective metabolism of 
Hcy in carcinogenesis is well documented, but the pathophysiology is 
not fully understood [33,34]. North American and Western European 
societies have a high risk of developing cancer due to low intake of 
vegetables and particularly folic acid in diets. Folic acid deficiency 
enables DNA damage to occur and accumulate. This can lead to DNA 
damage and cancer [35].
Diabetology
Hhcy is common in many diabetic patients and may contribute to the 
accelerated risk of atherosclerosis and CVD. The adverse vascular effect 
of Hcy in diabetes appears to be related primarily to type 2 diabetes 
mellitus (T2DM). In the west, the incidence of Hhcy in diabetic patients 
is reported to be approximately 5 times greater than the general 
population [27,36,37]. Hhcy is detected in patients with DM, which may 
contribute to the development of chronic complications. It correlates 
with both changes in glomerular filtration rate as well as the presence 
of microalbuminuria. Hcy concentrations correlate with the presence 
of diabetic peripheral neuropathy and have also been associated with 
the presence of autonomic neuropathy in patients with type 1 diabetes. 
Hcy elevation in patients with DM only occurs when renal function 
deteriorates. The influence of diabetes treatment on Hcy levels requires 
further advance observations. Therapy with insulin and medications 
such as metformin and glitazones can either raise or lower Hcy levels. 
Hhcy is known to be a risk factor for vascular occlusive diseases. Meigs 
et al. reported that Hhcy is an independent risk factor of CVD incidence 
in diabetic patients. Hhcy increased the risk of CVD by 1.6 times in 
diabetic patients. It increases the mortality in T2DM [38,39].
CONCLUSION
Over the past decade, Hcy related research provoke a huge amount of 
scientific literature and sparked a vigorous debate, as an emerging risk 
factor for neural tube defects (NTD) and non-communicable disease 
(NCDs), including type 2 diabetes and cancer. Kilmer MC Cully, in 
1960, concluded that mutation in Hcy related gene leads to increased 
risk of CVD. Certain drugs (adenosine analogs, d-penicillamine, 
N-acetylcysteine, estrogens, tamoxifen, and betaine) decrease blood 
Hcy concentration through different mechanisms (i.e., remethylation 
stimulation, inhibition of SAH hydrolase activity). In past two decades, 
numerous studies have been conducted in developed countries to 
explore Hhcy status and its determinants. The result of these studies 
suggests that it could be caused by environmental exposures, lifestyles 
habits, disease status, hormonal factors, and several drugs [40]. 
Patients with heart failure and documented Hhcy should be considered 
for therapy with folic acid, vitamins and increased intake of fruits and 
vegetables since treatment is effective, inexpensive, without risk, and 
may lower the risk of adverse cardiac events. Patients with heart failure, 
impaired renal function, and diabetes should be screened since the 
incidence of Hhcy in these patients appears to be quite high.
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